Compost Biologics (09926.HK) Announces the Company's Core Autonomously Developed, World-First Novel Tumor Immunotherapy Novel Drug Cadonilimab (PD-1/CTLA-4 Dual-Specific Antibody, R&D Code: AK104), Announced on Microsatellite High Instability High Instability (“MSI-H”) Late Solid Tumors Preliminary clinical data.

MSI-H is a gene subtype widely present in most solid tumors. The Checkmate142 study showed that the dual immunotherapy Opdivo combined with Yervoy treatment with 2-line and above MSI-H colorectal cancer had an objective alleviation rate (ORR) of 56% and a complete cure rate (CR) of 13%. At the same time, Cadonilimab has good safety in patients treated with late MSI-H, showing consistent with its known safety features.